Seminoma component of mixed testicular germ cell tumor shows a higher incidence of loss of heterozygosity than pure-type seminoma.


Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
02 2019
Historique:
received: 10 07 2018
revised: 07 09 2018
accepted: 13 09 2018
pubmed: 30 9 2018
medline: 16 11 2019
entrez: 30 9 2018
Statut: ppublish

Résumé

Using analysis of allelic loss (loss of heterozygosity [LOH]), we previously reported a putative progression pathway from germ cell neoplasia in situ (GCNIS) to seminoma and then to embryonal carcinoma in mixed-type testicular germ cell tumors. To identify the genetic backgrounds related to the progression of nonseminomatous germ cell tumor, patterns of LOH were studied in seminoma components in mixed tumors (18 cases), pure seminomas (20 cases), and coexisting GCNIS lesions. Each tumor was assessed for LOH at 22 polymorphic loci located on 12 chromosomal arms: 3q, 5q, 6p, 9p, 10q, 11p, 12p, 12q, 13q, 17p, 17q, and 18q. For all informative loci, the frequency of LOH in seminoma components in mixed tumors was significantly higher than that in pure seminomas (32% [96/302 loci] versus 19% [60/323 loci], P < .0001). The frequency of LOH in GCNIS lesions was not significantly different between the 2 tumor groups. The frequencies of LOH at chromosomes 6p and 10q were significantly higher in seminoma components in mixed tumors than in pure seminomas (P = .020 and P = .0041, respectively). Immunohistochemical analysis demonstrated a close association between the allelic status of the 10q23 locus and levels of phosphatase and tensin homolog deleted from chromosome 10 protein expression in seminoma (P = .00051). These data indicate that the seminoma, which has a potential to progress to nonseminomatous germ cell tumor, already exhibits several genetic changes including allelic losses of 6p and 10q, unlike pure seminoma.

Identifiants

pubmed: 30266250
pii: S0046-8177(18)30366-6
doi: 10.1016/j.humpath.2018.09.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-80

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Kosuke Miyai (K)

Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan; Department of Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan. Electronic address: mykusu228@nifty.com.

Keiichi Ito (K)

Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.

Kuniaki Nakanishi (K)

Department of Laboratory Medicine, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.

Hitoshi Tsuda (H)

Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH